NCT05538572View on ClinicalTrials.gov

A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 27, 2022

Primary Completion Date

June 26, 2024

Study Completion Date

June 26, 2024

Conditions
Breast CancerGlioblastomaHead and Neck Squamous Cell CarcinomaMalignant MesotheliomaNon-small Cell Lung CancersSarcomaEndometrial Cancer
Interventions
DRUG

PRT3645

PRT3645 capsules will be self-administered once daily, continuously, at the dose-level assigned

Trial Locations (13)

10016

Laura and Isaac Perlmutter Cancer Center/ NYU Langone Health, New York

19104

Hospital of the University of Pennsylvania, Philadelphia

19107

Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia

22031

NEXT Virginia, Fairfax

30322

Winship Cancer Institute, Emory University, Atlanta

33176

Miami Cancer Institute, Miami

34232

Florida Cancer Specialists, Sarasota

34747

AdventHealth Medical Group Oncology Research at Celebration, Celebration

37203

Tennessee Oncology, PLLC, Nashville

44195

Cleveland Clinic, Cleveland

78229

South Texas Accelerated Research Therapeutics, LLC, San Antonio

168583

National Cancer Centre Singapore, Singapore

06511

Smilow Cancer Hospital Phase 1 Unit, New Haven

Sponsors
All Listed Sponsors
lead

Prelude Therapeutics

INDUSTRY

NCT05538572 - A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter